- THE MAGAZINE
- Advertiser Index
- Raw & Manufactured Materials Overview
- Classifieds & Services Marketplace
- Product & Literature Showcases
- List Rental
- Market Trends
- Material Properties Charts
- Custom Content & Marketing Services
- CI Top 10 Advanced Ceramic Manufacturers
- Virtual Supplier Brochures
The two companies have entered into a letter of intent (LOI) for GENova to acquire a number of TheraGlass Ltd.’s patents. The deal is expected to close in the fourth quarter.
“The potential for augmenting cancer treatments with a regenerative product like TheraGlass is tremendous,” said Aaron Whiteman, GENova’s CEO. “While GENova's treatments destroy cancerous cells, TheraGlass can stimulate healthy cells to regenerate, thus expediting the healing process.”
TheraGlass Ltd. has an exclusive international position for the commercialization of sol-gel derived bioactive glass under the trade name TheraGlass. Discovered by Professor Larry Hench and developed at Imperial College London, TheraGlass is the next generation of bioactive glass, a medical device material that can interact with the body's hard and soft tissues to stimulate cell growth, accelerating the body’s self-healing properties.
For more information, visit www.genovabio.com.